United Kingdom Trial of Radioiodine Intervention for Subclinical Hyperthyroidism

英国放射性碘干预治疗亚临床甲状腺功能亢进症的试验

• 批准号: G0500783/1
• 负责人: Simon Pearce
• 金额: $ 22.52万
• 依托单位: Newcastle University
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2006
• 资助国家: 英国
• 起止时间: 2006 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0500783%2F1
• 关键词: United; Kingdom; Trial; Radioiodine; Intervention

Subclinical hyperthyroidism (SH) is a state of mild thyroid gland overactivity, defined by measurement of thyroid hormones in the blood. It is quite common, affecting about 2% of elderly people. Rather like high blood cholesterol levels, most people have no symptoms of SH, but it is associated with an increased risk of vascular disease. The problem is that we don`t know whether treating SH is worthwhile, in terms of benefit to vascular disease rates and other problems.We will carry out a trial comparing radioiodine treatment of the thyroid gland overactivity to standard therapy for cardiac risk factors in patients with SH. We will follow people with SH for 5 years after the treatment to find out whether this improves the rate of vascular diseases and other problems. This trial will form the first randomised study of treatment for this condition and will inform healthcare decision making for about 200,000 elderly people each year in the UK.

亚临床甲状腺功能亢进症(SH)是一种轻微的甲状腺过度活动状态，通过测量血液中的甲状腺激素来定义。这很常见，大约2%的老年人会受到影响。与高血胆固醇水平不同，大多数人没有SH症状，但它与血管疾病风险的增加有关。问题是，我们不知道从血管疾病发生率和其他问题的益处来看，治疗甲状腺功能亢进是否值得。我们将对甲状腺功能亢进的放射性碘治疗与心脏危险因素的标准治疗进行比较。我们将在治疗后对患有SH的人进行为期5年的跟踪，以了解这是否会改善血管疾病和其他问题的发生率。这项试验将形成第一项针对这种疾病的随机治疗研究，并将为英国每年约20万名老年人的医疗决策提供信息。